8-K: Biotricity Amends At-The-Market Offering Agreement, Plans $2.68 Million Share Sale

Biotricity Inc. has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $2.68 million of its common stock.

Summary

• Biotricity Inc. has entered into an amendment to its existing At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC.
• This amendment allows Biotricity to sell shares of its common stock from time to time through Wainwright.
• The amendment is related to a new registration statement on Form S-3, which was filed on May 8, 2024, and became effective on May 15, 2024.
• Biotricity plans to offer and sell an aggregate of $2,684,644 of its common stock under this amended agreement.
• The shares will be issued under the new registration statement and a related prospectus supplement dated May 28, 2024.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard capital raising activity, which is necessary for the company's operations. There are no indications of significant positive or negative events.

Positives

• The amendment provides Biotricity with a mechanism to raise capital through the sale of its common stock.
• The new registration statement allows for the efficient sale of shares.
• The company has secured legal opinions regarding the legality of the shares being issued.

Risks

• The sale of additional shares may dilute the value of existing shares.
• Market conditions could impact the company's ability to sell the shares at the desired price.
• The company is reliant on H.C. Wainwright & Co., LLC for the sale of shares.

Future Outlook

Biotricity intends to sell up to $2,684,644 of its common stock through H.C. Wainwright & Co., LLC, as sales agent, under the amended agreement.

Management Comments

• Waqaas Al-Siddiq, Chief Executive Officer, signed the amendment on behalf of Biotricity Inc.

Industry Context

At-the-market offerings are a common method for companies to raise capital, particularly in the biotech and healthcare sectors. This allows for flexible and opportunistic sales of shares based on market conditions.

Comparison to Industry Standards

• At-the-market offerings are a standard practice for companies seeking to raise capital without a traditional underwritten offering.
• The size of the offering, $2.68 million, is relatively small compared to some larger biotech companies, but is typical for companies of Biotricity's size and stage.
• The use of H.C. Wainwright & Co., LLC as a sales agent is common, as they have experience in this type of transaction.

Stakeholder Impact

• Shareholders may experience dilution of their ownership stake due to the issuance of new shares.
• The capital raise could provide the company with additional resources to fund its operations and growth.

Next Steps

• Biotricity will proceed with the sale of its common stock through H.C. Wainwright & Co., LLC.
• The company will monitor market conditions to determine the timing and price of share sales.

Key Dates

Keywords

At-The-Market Offering, Common Stock, Share Sale, Capital Raise, Biotricity, H.C. Wainwright, Registration Statement, Securities